Robotti Robert Has Upped By $1.15 Million Its Radnet (RDNT) Position; Shorts at Htg Molecular Diagnostics (HTGM) Lowered By 12.39%

February 13, 2018 - By Henry Gaston

Robotti Robert increased Radnet Inc (RDNT) stake by 14.09% reported in 2017Q3 SEC filing. Robotti Robert acquired 104,622 shares as Radnet Inc (RDNT)’s stock rose 23.39%. The Robotti Robert holds 846,938 shares with $9.78M value, up from 742,316 last quarter. Radnet Inc now has $481.00M valuation. The stock increased 1.51% or $0.15 during the last trading session, reaching $10.1. About 52,948 shares traded. RadNet, Inc. (NASDAQ:RDNT) has risen 53.92% since February 13, 2017 and is uptrending. It has outperformed by 37.22% the S&P500.




Htg Molecular Diagnostics Incorporated (NASDAQ:HTGM) had a decrease of 12.39% in short interest. HTGM’s SI was 1.75 million shares in February as released by FINRA. Its down 12.39% from 2.00 million shares previously. With 274,000 avg volume, 6 days are for Htg Molecular Diagnostics Incorporated (NASDAQ:HTGM)’s short sellers to cover HTGM’s short positions. The SI to Htg Molecular Diagnostics Incorporated’s float is 50.6%. The stock increased 2.06% or $0.0836 during the last trading session, reaching $4.1336. About 2.52 million shares traded or 87.13% up from the average. HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) has risen 34.13% since February 13, 2017 and is uptrending. It has outperformed by 17.43% the S&P500.

Among 3 analysts covering RadNet (NASDAQ:RDNT), 2 have Buy rating, 0 Sell and 1 Hold. Therefore 67% are positive. RadNet had 6 analyst reports since March 15, 2016 according to SRatingsIntel. The rating was initiated by Sidoti with “Buy” on Friday, April 15. The rating was maintained by Jefferies with “Hold” on Tuesday, March 15. Jefferies maintained RadNet, Inc. (NASDAQ:RDNT) on Thursday, July 13 with “Hold” rating. The stock of RadNet, Inc. (NASDAQ:RDNT) earned “Neutral” rating by Sterne Agee CRT on Thursday, June 2. Jefferies upgraded the stock to “Buy” rating in Tuesday, August 22 report. Jefferies maintained RadNet, Inc. (NASDAQ:RDNT) rating on Thursday, November 9. Jefferies has “Buy” rating and $12.0 target.

HTG Molecular Diagnostics, Inc. develops and markets services and products based on proprietary technology that facilitates the routine use of targeted molecular profiling. The company has market cap of $115.10 million. The companyÂ’s products, HTG Edge and HTG EdgeSeq platforms include instrumentation , consumables comprising assay kits, and software analytics that automate sample processing and profiles various molecular targets from samples a fraction of the size required by prevailing technologies. It currently has negative earnings. The Company’s platforms generate a molecular profiling library for detection using next-generation sequencing.

Among 3 analysts covering HTG Molecular Diagnostics (NASDAQ:HTGM), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. HTG Molecular Diagnostics had 14 analyst reports since August 24, 2015 according to SRatingsIntel. The stock of HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) has “Buy” rating given on Wednesday, January 24 by H.C. Wainwright. The company was initiated on Monday, August 22 by Rodman & Renshaw. The firm has “Buy” rating by Canaccord Genuity given on Tuesday, November 24. H.C. Wainwright maintained the stock with “Buy” rating in Wednesday, November 8 report. The firm has “Buy” rating by H.C. Wainwright given on Wednesday, August 9. H.C. Wainwright maintained the shares of HTGM in report on Tuesday, September 12 with “Buy” rating. H.C. Wainwright maintained the stock with “Buy” rating in Friday, January 5 report. H.C. Wainwright maintained HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) on Thursday, June 29 with “Buy” rating. Canaccord Genuity maintained it with “Buy” rating and $5.0 target in Friday, January 5 report. The firm has “Buy” rating by Canaccord Genuity given on Monday, August 24.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Recent Posts